The high-yield circular production method of taurine includes the following steps: S1, ethylene oxide reacts with sodium bisulfite solution to generate sodium hydroxyethyl sulfonate; S2, sodium hydroxyethyl sulfonate obtained in S1 is subjected to ammonolysis reaction in ammonia, and ammonia gas is recycled through flash evaporation upon completion of the reaction; S3, a reaction solution obtained after flash evaporation in S2 is sent to pass through an acidic cation exchange resin column, a material liquid containing taurine is collected, the inactivated resin column is subjected to regeneration with sulfur dioxide or carbon dioxide aqueous solution, and an eluent acquired during regeneration can be recycled directly or recycled after treated by sulfur dioxide; S4, the material liquid collected in S3 is subjected to post treatment to acquire taurine.

The present invention relates to novel cycloalkyl-hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, Syndrome X, thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

The present invention relates to novel cycloalkyl-hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, Syndrome X, thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

The present application provides a process for preducing taurine, comprising the steps as follows: (a) mixing isethionic acid with taurine salt solution until the system pH reaches a certain value in a range from 5.0 to 9.5; (b) separating liquid phase and solid phase of the system; wherein said solid phase is the crude product of taurine, and said liquid phase is isethionate solution; (c) reacting ammonia solution with said liquid phase obtained from step (b) to obtain taurine salt solution. It uses isethionic acid to adjust the pH of the taurine salt solution, avoiding the problem causing by using sulphate acid to adjust the pH in the traditional process. By the recycling use of the cations in taurine salts, a new raw material or reagent does not need to be added which is benefit to reducing the use of dangerous chemical materials, simplifying the production process greatly, improving the utilization rate of raw materials, increasing the yield of the product and decreasing production cost significantly.

The present application provides a process for preducing taurine, comprising the steps as follows: (a) mixing isethionic acid with taurine salt solution until the system pH reaches a certain value in a range from 5.0 to 9.5; (b) separating liquid phase and solid phase of the system; wherein said solid phase is the crude product of taurine, and said liquid phase is isethionate solution; (c) reacting ammonia solution with said liquid phase obtained from step (b) to obtain taurine salt solution. It uses isethionic acid to adjust the pH of the taurine salt solution, avoiding the problem causing by using sulphate acid to adjust the pH in the traditional process. By the recycling use of the cations in taurine salts, a new raw material or reagent does not need to be added which is benefit to reducing the use of dangerous chemical materials, simplifying the production process greatly, improving the utilization rate of raw materials, increasing the yield of the product and decreasing production cost significantly.

The present application provides a process for preducing taurine, comprising the steps as follows: (a) mixing isethionic acid with taurine salt solution until the system pH reaches a certain value in a range from 5.0 to 9.5; (b) separating liquid phase and solid phase of the system; wherein said solid phase is the crude product of taurine, and said liquid phase is isethionate solution; (c) reacting ammonia solution with said liquid phase obtained from step (b) to obtain taurine salt solution. It uses isethionic acid to adjust the pH of the taurine salt solution, avoiding the problem causing by using sulphate acid to adjust the pH in the traditional process. By the recycling use of the cations in taurine salts, a new raw material or reagent does not need to be added which is benefit to reducing the use of dangerous chemical materials, simplifying the production process greatly, improving the utilization rate of raw materials, increasing the yield of the product and decreasing production cost significantly.

Since biomass is always accompanied by caustic inorganic materials, we have found that the formation of the anion salt of -hydroxysulfonic acid represent the largest loss of the -hydroxysulfonic acid in the potential reversible acid pretreatment process. By titrating the -hydroxysulfonic acid salt with strong mineral acid and then reverting the alfa-hydroxysulfonic acid as its primary components, the acid components can be recovered substantially quantitatively.

Since biomass is always accompanied by caustic inorganic materials, we have found that the formation of the anion salt of -hydroxysulfonic acid represent the largest loss of the -hydroxysulfonic acid in the potential reversible acid pretreatment process. By titrating the -hydroxysulfonic acid salt with strong mineral acid and then reverting the alfa-hydroxysulfonic acid as its primary components, the acid components can be recovered substantially quantitatively.

Pharmaceutically acceptable salts, esters and conjugates of psilocin and compositions and methods for their production and use in treating diseases or conditions treatable with psilocin or psilocybin are provided.

A lyophilisate of treosulfan is described which possesses favourable characteristics in terms of a short reconstitution time and a high purity and stability and which is particularly useful in the treatment of cancer and for conditioning therapy before transplantation of bone marrow or blood stem cells.